![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Vicore Pharma Releases Positive Phase 2 Results for COVID-19 Oral Therapy
Vicore Pharma Releases Positive Phase 2 Results for COVID-19 Oral Therapy
![COVID-19 Clinical Trial](https://www.fdanews.com/ext/resources/test/Drug-Images4/COVID-19-CLINICAL-TRIAL.gif?t=1585696642&width=430)
Swedish drugmaker Vicore Pharma has reported positive results from a phase 2 study evaluating its oral therapy for treating respiratory infection in hospitalized COVID-19 patients.
The study enrolled 106 infected patients randomized to receive the investigational drug or placebo, with those taking the oral COVID-19 therapy, C21, shown to have a 40 percent reduced risk of requiring supplemental oxygen following seven days of treatment and a 57 percent reduced risk at eight days.
“Our data clearly show that C21 can restore lung function on top of steroids and normalize gas exchange,” said Vicore CEO Carl-Johan Dalsgaard. “A safe oral medication with such properties can become an important complement to vaccines to combat the pandemic.”
Upcoming Events
-
21Oct